Tom Neyarapally

Bio:

Tom Neyarapally, JD, MBA, Chief Executive Officer and Co-Founder, Archetype Therapeutics, was most recently founding team member and CCO of the health information and genetic testing company Sema4, where his strategic commercial leadership led to the company’s core genetic testing product volume growing 350%+ in two years and revenue reaching $200M, resulting in Sema4 going public at a multi-billion dollar valuation.  

Prior to Sema4, Tom was co-founder and EVP Corporate Development at GNS Healthcare (now Aitia), a leader in life sciences data and analytics, where he was a co-inventor on the company’s foundational platform, REFS™.  Earlier in his career, Tom practiced corporate and IP law in New York, and was a management consultant at Arthur D. Little.  Tom earned a BS in Chemical Engineering from the University of Connecticut, cum laude/Honors Scholar, and his JD and MBA degrees from Cornell University, and is a USPTO-registered Patent Agent.